MESO-WHARTON BIOREVITALIZATION

Meso-Wharton P199 is a new generation injection treatment of high efficiency achieved by means of deep tissue repair at the cellular level. Meso-Wharton is developed by the U.S. ABG Lab LLC company and is produced on a pharmaceutical factory in South Korea. The medicine is approved by the U.S. Department of Health and Human Services. Meso-Wharton is a treatment that is specifically designed for intensive rejuvenation of the skin of face and body in patients over 40 years of age.

The main active ingredient of the treatment is an embryonic peptide analogue (WhartonJellyPeptide Ð199), produced by the synthetic method. It conduces to the synthesis of proper stem cells, elastin fibers, and hyaluronic acid.

Meso-Wharton is the only biorevitalizing treatment that works at the cellular level. It’s unique due to the presence of high molecular hyaluronic acid, amino acid complex, nucleic acids and vitamins in its formulation.

Meso-Wharton P199 not only moisturizes intensively the skin, but also stimulates actively the rejuvenation processes, conduces to proper stem cell expansion, which provides skin turnover and enrichment with vitamins and microelements. • Age-related skin changes (wrinkles, tone and elasticity loss, tissue ptosis)
• Wrinkles and folds in the decollate area
• Dry, dehydrated skin
• Face contour changes
• Hyperpigmentation
• Need for treatment after middle or deep peeling, burns
• Preparation for plastic surgery
• Need for post-operational skin rehabilitation • Inflammatory processes in the acute phase in the area potential for the injection
• Hypersensitivity to components of the formulation
• Pregnancy and breastfeeding
• Autoimmune diseases
• Compromised immunity
• Foreign bodies in the area potential for the injection Before the procedure, the specialist-dermatocosmetologist examines the patient's skin, collects detailed information about the health of the patient and undertaken cosmetic procedures, and finds out if the patient has any chronic diseases or allergic reactions.
If there are indications to the procedure, then the specialist chooses a biorevitalizing filler corresponding to the patient’s skin type, which is designed for solution of particular problems.
Before the procedure, the skin is to be cleaned; make-up removal with the use of cosmetic units, as well as chlorhexidine antiseptic solution treatment are carried out.
By the patient’s request, the local anesthesia (EMLA cream) is applied. The specialist chooses an injection technique in accordance with the skin condition and thickness in the treatment area as well as with wrinkle and spider veins intensity.

Number of procedures depends on the patient’s age and preoperational state of the skin. A 6-procedure course is usually recommended to women under 45, while the 8-procedure one is indicated to those over 45. 4 to 6 first injections are carried out with 6 to 7-day pauses. The closing two procedures follow with a 2-week interval. Retreatment may be carried out in a 6 to 12 months’ time. • Skin firmness and elasticity improvement
• Lift effect
• Skin microrelief resurfacing
• Small wrinkle resurfacing
• Skin hydration
• Facial contour improvement
• Hyperpigmentation treatment Avoid going to sauna, bath house, swimming pool or gym on a procedure day
Just after the procedure avoid applying everyday cosmetic products
Within two days after the procedure administer a medicinal product with regenerative and vessel-strengthening action, conductive to a faster recovery after the procedure